Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity to Asset 0.55
NVS's Equity to Asset is ranked lower than
61% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.55
0.51
0.65
Interest Coverage 12.24
NVS's Interest Coverage is ranked lower than
59% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. NVS: 12.24 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 13.42  Med: 16.32 Max: 30.91
Current: 12.24
13.42
30.91
F-Score: 5
Z-Score: 2.58
M-Score: -2.65
WACC vs ROIC
7.11%
7.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.97
NVS's Operating margin (%) is ranked higher than
76% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. NVS: 16.97 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 17.41  Med: 20.34 Max: 22.35
Current: 16.97
17.41
22.35
Net-margin (%) 13.55
NVS's Net-margin (%) is ranked higher than
76% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. NVS: 13.55 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 15.35  Med: 19.02 Max: 35.29
Current: 13.55
15.35
35.29
ROE (%) 9.04
NVS's ROE (%) is ranked higher than
58% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. NVS: 9.04 )
Ranked among companies with meaningful ROE (%) only.
NVS' s ROE (%) Range Over the Past 10 Years
Min: 12.6  Med: 15.32 Max: 25.73
Current: 9.04
12.6
25.73
ROA (%) 5.13
NVS's ROA (%) is ranked higher than
59% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. NVS: 5.13 )
Ranked among companies with meaningful ROA (%) only.
NVS' s ROA (%) Range Over the Past 10 Years
Min: 7.21  Med: 8.97 Max: 16.18
Current: 5.13
7.21
16.18
ROC (Joel Greenblatt) (%) 44.71
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. NVS: 44.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 39.09  Med: 59.49 Max: 69.76
Current: 44.71
39.09
69.76
Revenue Growth (3Y)(%) -1.30
NVS's Revenue Growth (3Y)(%) is ranked lower than
70% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NVS: -1.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.1  Med: 4.70 Max: 75.8
Current: -1.3
-2.1
75.8
EBITDA Growth (3Y)(%) -6.80
NVS's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. NVS: -6.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 5.40 Max: 81.6
Current: -6.8
-10.5
81.6
EPS Growth (3Y)(%) -7.20
NVS's EPS Growth (3Y)(%) is ranked lower than
69% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NVS: -7.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.2  Med: 5.90 Max: 83.5
Current: -7.2
-7.2
83.5
» NVS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NVS Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 1,286,303 sh (+255.53%)
Sarah Ketterer 236,714 sh (+6.32%)
Ken Fisher 6,054,640 sh (+1.08%)
Pioneer Investments 83,144 sh (+0.24%)
First Eagle Investment 12,848 sh (unchged)
Mairs and Power 4,080 sh (unchged)
RS Investment Management 2,825 sh (unchged)
PRIMECAP Management 22,137,858 sh (-0.17%)
Murray Stahl 27,350 sh (-0.73%)
Tweedy Browne 254,217 sh (-2.31%)
Jim Simons 1,186,598 sh (-3.36%)
Dodge & Cox 47,970,345 sh (-4.12%)
Kahn Brothers 28,143 sh (-9.12%)
Mario Gabelli 8,330 sh (-15.35%)
John Hussman 100,000 sh (-33.33%)
» More
Q3 2015

NVS Guru Trades in Q3 2015

Manning & Napier Advisors, Inc 2,780,106 sh (+116.13%)
Jim Simons 1,682,398 sh (+41.78%)
Sarah Ketterer 262,666 sh (+10.96%)
Murray Stahl 28,750 sh (+5.12%)
Kahn Brothers 28,543 sh (+1.42%)
Ken Fisher 6,132,211 sh (+1.28%)
Mairs and Power 4,080 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
RS Investment Management 2,825 sh (unchged)
Pioneer Investments Sold Out
Tweedy Browne 249,022 sh (-2.04%)
Dodge & Cox 45,723,035 sh (-4.68%)
PRIMECAP Management 20,815,508 sh (-5.97%)
Mario Gabelli 7,540 sh (-9.48%)
John Hussman 50,000 sh (-50.00%)
» More
Q4 2015

NVS Guru Trades in Q4 2015

John Rogers 11,267 sh (New)
Jim Simons 3,091,198 sh (+83.74%)
Manning & Napier Advisors, Inc 3,507,436 sh (+26.16%)
Sarah Ketterer 281,710 sh (+7.25%)
Ken Fisher 6,188,893 sh (+0.92%)
First Eagle Investment 12,848 sh (unchged)
Murray Stahl 28,750 sh (unchged)
Mairs and Power 4,080 sh (unchged)
Samuel Isaly 895,000 sh (unchged)
RS Investment Management Sold Out
John Hussman Sold Out
PRIMECAP Management 20,768,108 sh (-0.23%)
Dodge & Cox 45,107,085 sh (-1.35%)
Mario Gabelli 7,390 sh (-1.99%)
Tweedy Browne 242,201 sh (-2.74%)
Kahn Brothers 27,643 sh (-3.15%)
» More
Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Samuel Isaly 457,700 sh (-48.86%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:MRK, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.

Ratios

vs
industry
vs
history
P/E(ttm) 29.95
NVS's P/E(ttm) is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. NVS: 29.95 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.80 Max: 29.97
Current: 29.95
5.7
29.97
Forward P/E 17.54
NVS's Forward P/E is ranked lower than
58% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. NVS: 17.54 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.39
NVS's PE(NRI) is ranked lower than
54% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. NVS: 30.39 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.11 Max: 31.15
Current: 30.39
10.63
31.15
Price/Owner Earnings (ttm) 19.84
NVS's Price/Owner Earnings (ttm) is ranked higher than
73% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. NVS: 19.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.74 Max: 23.92
Current: 19.84
7.18
23.92
P/B 2.78
NVS's P/B is ranked higher than
52% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. NVS: 2.78 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.48 Max: 4.14
Current: 2.78
1.69
4.14
P/S 4.05
NVS's P/S is ranked lower than
62% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. NVS: 4.05 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 3.26 Max: 5.01
Current: 4.05
1.88
5.01
PFCF 22.96
NVS's PFCF is ranked lower than
52% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. NVS: 22.96 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 16.83 Max: 26.84
Current: 22.96
7.05
26.84
POCF 16.95
NVS's POCF is ranked lower than
51% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. NVS: 16.95 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.10 Max: 19.4
Current: 16.95
5.77
19.4
EV-to-EBIT 26.16
NVS's EV-to-EBIT is ranked lower than
63% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. NVS: 26.16 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.60 Max: 27
Current: 26.16
8.5
27
EV-to-EBITDA 17.52
NVS's EV-to-EBITDA is ranked lower than
52% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. NVS: 17.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.10 Max: 18.1
Current: 17.52
7.3
18.1
Shiller P/E 16.77
NVS's Shiller P/E is ranked higher than
87% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. NVS: 16.77 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.7  Med: 14.28 Max: 21.62
Current: 16.77
9.7
21.62
Current Ratio 0.90
NVS's Current Ratio is ranked lower than
91% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. NVS: 0.90 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.39 Max: 2.83
Current: 0.9
0.83
2.83
Quick Ratio 0.65
NVS's Quick Ratio is ranked lower than
91% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. NVS: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.14 Max: 2.48
Current: 0.65
0.59
2.48
Days Inventory 134.29
NVS's Days Inventory is ranked lower than
61% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. NVS: 134.29 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 142.51 Max: 183.42
Current: 134.29
117.85
183.42
Days Sales Outstanding 62.45
NVS's Days Sales Outstanding is ranked higher than
59% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. NVS: 62.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 62.36 Max: 69.89
Current: 62.45
56.31
69.89
Days Payable 100.98
NVS's Days Payable is ranked higher than
69% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.26 vs. NVS: 100.98 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 88.14  Med: 111.44 Max: 120.63
Current: 100.98
88.14
120.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.27
NVS's Dividend Yield is ranked higher than
90% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. NVS: 3.27 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.27 Max: 5.11
Current: 3.27
1.47
5.11
Dividend Payout 0.98
NVS's Dividend Payout is ranked lower than
88% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. NVS: 0.98 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 1.12  Med: 1.67 Max: 3.22
Current: 0.98
1.12
3.22
Dividend Growth (3y) 5.40
NVS's Dividend Growth (3y) is ranked lower than
55% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. NVS: 5.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.80 Max: 18.5
Current: 5.4
0
18.5
Forward Dividend Yield 3.25
NVS's Forward Dividend Yield is ranked higher than
80% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. NVS: 3.25 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.56
NVS's Yield on cost (5-Year) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. NVS: 4.56 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.05  Med: 4.56 Max: 7.13
Current: 4.56
2.05
7.13
3-Year Average Share Buyback Ratio 0.60
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. NVS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -224.6  Med: 0.10 Max: 2.3
Current: 0.6
-224.6
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.25
NVS's Price/Tangible Book is ranked lower than
96% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. NVS: 26.25 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.16  Med: 4.27 Max: 12455
Current: 26.25
0.16
12455
Price/Projected FCF 1.33
NVS's Price/Projected FCF is ranked higher than
77% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. NVS: 1.33 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.12 Max: 2.52
Current: 1.33
0.65
2.52
Price/Median PS Value 1.25
NVS's Price/Median PS Value is ranked lower than
59% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. NVS: 1.25 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.15 Max: 3.11
Current: 1.25
0.64
3.11
Price/Graham Number 5.95
NVS's Price/Graham Number is ranked lower than
88% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. NVS: 5.95 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.97 Max: 81.67
Current: 5.95
0.43
81.67
Earnings Yield (Greenblatt) (%) 3.82
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. NVS: 3.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.40 Max: 11.8
Current: 3.82
3.7
11.8
Forward Rate of Return (Yacktman) (%) 3.17
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. NVS: 3.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 14.20 Max: 69.3
Current: 3.17
1
69.3

More Statistics

Revenue (TTM) (Mil) $49,778
EPS (TTM) $ 2.81
Beta0.62
Short Percentage of Float0.18%
52-Week Range $69.90 - 104.75
Shares Outstanding (Mil)2,381.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,351 50,753 55,501
EPS ($) 4.84 5.10 6.14
EPS w/o NRI ($) 4.84 5.10 6.14
EPS Growth Rate
(3Y to 5Y Estimate)
3.75%
Dividends Per Share ($) 2.79 2.90 3.13
» More Articles for NYSE:NVS

Headlines

Articles On GuruFocus.com
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Causeway International Value Fund May Performance Review Jul 08 2016 
Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies Jun 13 2016 
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Valeant's Share Price Continues to Decline Feb 05 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 

More From Other Websites
How Do the Majority of Analysts Rate Novartis after 2Q16? Jul 25 2016
Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other Jul 22 2016
GlaxoSmithKline Segments That Drive Company’s Rising Revenues Jul 22 2016
What Role Did Innovative Medicines Play in Novartis’s 2Q16 Earnings? Jul 22 2016
What Are Lilly’s 2Q16 Estimates and Expectations for Elanco? Jul 22 2016
Research Reports on Facebook (FB), Tesla (TSLA) & Others Jul 21 2016
Inside the Foreign Exchange Impact on Novartis’s Growth in 2Q16 Jul 21 2016
How Did Novartis’s 2Q16 Earnings Stand up to Analyst Estimates? Jul 21 2016
Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science Jul 21 2016
Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow Jul 20 2016
Pricing dispute hits supply of TB drugs in Pakistan Jul 19 2016
Amgen Finally Scores a Win in Its Big Copycat Drug Battle With Novartis Jul 19 2016
Novartis Shares Slip Tuesday on Falling Profit Jul 19 2016
What Lilly Expects for Revenue Growth in 2Q16 Jul 19 2016
Novartis Set To Become Biosimilar Pioneer By 2020 Jul 19 2016
Novartis Set To Become Biosimilar Pioneer By 2020 Jul 19 2016
ETF’s with exposure to Novartis AG : July 19, 2016 Jul 19 2016
Novartis profit slips as generic drug competition hits sales Jul 19 2016
Novartis profit slips as generic drug competition hits sales Jul 19 2016
Novartis in no rush to sell down stake on GSK consumer venture Jul 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)